AbCellera Biologics Inc vs Best Buy Co Inc — how do they compare? AbCellera Biologics Inc trades at $9.03 (market cap $2.99B), while Best Buy Co Inc trades at $83.5 (market cap $17.55B). The key difference: Best Buy Co Inc is far larger — about 5.9× AbCellera Biologics Inc's market cap, and Best Buy Co Inc pays a 4.61% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BBY | |
|---|---|---|
Market Cap | $2.99B | $17.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $90.17 |
52-Week Low | $2.78 | $55.52 |
Enterprise Value | $2.58B | $19.93B |
Dividend Yield | — | 4.61% |
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →